➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Medtronic
Baxter
Boehringer Ingelheim

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,536,122


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,536,122
Title:Acylated GLP-1 compounds
Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
Inventor(s): Lau; Jesper (Farum, DK), Doerwald; Florencio Zaragoza (Smorum, DK), Bloch; Paw (Taastrup, DK), Hansen; Thomas Kruse (Herlev, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:13/412,283
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Recent additions to Drugs Protected by US Patent 8,536,122

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,536,122

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-001 Dec 5, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS ⤷  Free Forever Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-002 Apr 9, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS ⤷  Free Forever Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-001 Sep 20, 2019 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,536,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05102171Mar 18, 2005

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Baxter
Dow
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.